Novo Nordisk’s (NVO) Q4 Earnings and Sales Beat Estimates Posted byZacks Equity Research February 2, 2022 Leave a comment on Novo Nordisk’s (NVO) Q4 Earnings and Sales Beat Estimates Novo Nordisk’s (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.